A Study of Bleeding and Treatment in Participants With Von Willebrand Disease (NCT06610201)
Velora Discover: A Prospective, Screening Study of Bleeding and Treatment in Participants With Von Willebrand Disease
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this screening study is to accumulate information regarding bleeding events, quality of life, and the social and clinical impact of bleeds in participants with Von Willebrand Disease (VWD). Data from this study will be used to establish baseline bleeding and treatment rates in a population of participants with VWD and act as comparator data for future clinical study outcomes.(e.g. Velora Pioneer)
Who can join: Review the eligibility criteria below.
Location: Phoenix Children's Hospital — Phoenix, Arizona
Age range: 16 Years
🧪 Interventions in This Study
- Clinical outcomes of patients with VWD, Type 1 (OTHER)
- Clinical outcomes of patients with VWD, Type 2A, Type 2M, Type 2N, or Type 3 (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (17 Sites)
- Phoenix Children's Hospital — Phoenix, Arizona
- Arkansas Children's Hospital — Little Rock, Arkansas
- Children's Hospital of Los Angeles — Los Angeles, California
- University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center — Miami, Florida
- Emory Children's Center — Atlanta, Georgia
- Innovative Hematology, Inc./Indiana Hemophilia and Thrombosis Center — Indianapolis, Indiana
- Tulane University School of Medicine — New Orleans, Louisiana
- University of Michigan Hospitals, Department of Hemophilia and Coagulation Disorders — Ann Arbor, Michigan
- Mayo Clinic - Rochester — Rochester, Minnesota
- Oregon Health & Science University — Portland, Oregon
- Hemophilia Center of Western Pennsylvania — Pittsburgh, Pennsylvania
- The University of Texas Southwestern Medical Center — Dallas, Texas
- Washington Institute For Coagulation (WIC) — Seattle, Washington
- Fiona Stanley Hospital — Murdoch, Perth
- Royal Prince Alfred Hospital — Camperdown, Sydney
- The Alfred Hospital — Melbourne, Victoria
- Richmond Pharmacology — London,
📞 Contact the Study Coordinator
Phone: +1 888 493 8148; 080 8304 6409
Email: Clinicaltrials@hemab.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Von Willebrand Disease (VWD)
- A Study Assessing HMB-002 in Participants With Von Willebrand Disease — Phoenix, Arizona
- Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD) — Little Rock, Arkansas
- A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD) — Birmingham, Alabama
- HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB — Los Angeles, California
Explore by condition: All Von Willebrand Disease (VWD) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.